Deborah Brown Purchases 25,000 Shares of Oncolytics Biotech (TSE:ONC) Stock

Oncolytics Biotech Inc. (TSE:ONC) Director Deborah Brown acquired 25,000 shares of the business’s stock in a transaction on Thursday, February 12th. The stock was acquired at an average price of C$1.17 per share, with a total value of C$29,250.00. Following the transaction, the director owned 109,851 shares in the company, valued at approximately C$128,525.67. The trade was a 29.46% increase in their position.

Oncolytics Biotech Price Performance

The company has a market cap of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80. The business’s 50-day moving average is C$14.90 and its 200 day moving average is C$13.02. Oncolytics Biotech Inc. has a 12 month low of C$0.44 and a 12 month high of C$2.08. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75.

Oncolytics Biotech (TSE:ONC) last announced its earnings results on Wednesday, November 12th. The company reported C($0.14) earnings per share for the quarter. On average, sell-side analysts expect that Oncolytics Biotech Inc. will post -0.41 EPS for the current year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.